XG005 for Pain Control in Subjects Undergoing Bunionectomy

Completed · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Acute Pain

In brief

This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy. Subjects will be confined in the clinic from check-in through 72 hours post-surgery to monitor subject safety.

Key facts

Study ID

NCT06017999

Run by

Xgene Pharmaceutical Group

People needed

450

Starts

2023-08-29

Expected to finish

2024-09-30

Last updated by the study team

2025-11-17

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Arizona Research Center — Phoenix, Arizona, United States
• Pacific Research Network — San Diego, California, United States
• Clinical Pharmacology of Miami — Hialeah, Florida, United States
• Midwest Clinical Research Center — Dayton, Ohio, United States
• First Surgical Hospital — Bellaire, Texas, United States
• Legent Orthopedic Hospital — Carrollton, Texas, United States
• Memorial Hermann Village — Houston, Texas, United States
• Endeavor Clinical Trials — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.